Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,849 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers

Characterizing Skin Microbiome Change in Atopic Dermatitis

NCT04800185
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
Crisaborole 2% Top Oint, Skin Microbiome Swabs
Drug · Genetic
Lead sponsor
University of California, Irvine
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Conditions
X-linked Hypohidrotic Ectodermal Dysplasia
Interventions
EDI200
Drug
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California • Cincinnati, Ohio
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), EPP2
Interventions
PORT-77, Placebo
Drug
Lead sponsor
Portal Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Huntington Beach, California • Cincinnati, Ohio
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 5 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Oakland, California • Manhasset, New York
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis, Deformity of Knee
Interventions
Physica Kinematic Retaining Knee System, Physica Cruciate Retaining Knee System, Physica Posterior Stabilized Knee System, Physica Cruciate Retaining Knee System with LMC Liner
Device
Lead sponsor
Limacorporate S.p.a
Industry
Eligibility
22 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
5
States / cities
Rancho Mirage, California • Daytona Beach, Florida • Aurora, Illinois + 2 more
Conditions
Dermatitis, Atopic
Interventions
Placebo, Bermekimab, Dupilumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Santa Ana, California • Orange Park, Florida + 15 more
Completed No phase listed Observational Accepts healthy volunteers

A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions

NCT01014819
Conditions
Basal Cell Carcinoma
Interventions
Not listed
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oakland, California
Conditions
Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Zoledronic Acid
Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
95
States / cities
Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more
Conditions
Osteogenesis Imperfecta (OI)
Interventions
Denosumab, Alternative osteoporosis medications
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Indianapolis, Indiana
Conditions
Morquio Syndrome A, Maroteaux Lamy Syndrome, MPS IVA, MPS VI
Interventions
Not listed
Lead sponsor
Greenwood Genetic Center
Other
Eligibility
Up to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Greenville, South Carolina
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 1 more
Conditions
MPS I, MPS II, MPS IVA, MPS VI, Mps VII, Gaucher Disease, Type 2, Gaucher Disease, Type 3, Pompe Disease Infantile-Onset, Wolman Disease
Interventions
Aldurazyme (laronidase)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
San Francisco, California
Conditions
Mucopolysaccharidosis III
Interventions
anakinra
Biological
Lead sponsor
Lynda E Polgreen
Other
Eligibility
4 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Torrance, California
Conditions
Generalised Lipodystrophy, Partial Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 11 more
Conditions
Epidermolysis Bullosa
Interventions
topical BPM31510 3.0% Cream
Drug
Lead sponsor
Shasa Hu
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
Atopic Dermatitis
Interventions
Locoid Lipocream, Hylatopic Plus
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Approved For Marketing No phase listed Expanded access

BMN 110 US Expanded Access Program

NCT01858103
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
250 participants
Timeline
2023 – 2027
U.S. locations
10
States / cities
Glendale, California • Mountain View, California • Carmel, Indiana + 7 more
Conditions
Netherton Syndrome
Interventions
Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection, Placebo matching to spesolimab - solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more